- Conditions
- Osteoporosis
- Interventions
- placebo, ALX1-11
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 2,532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 95 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 294
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Osteoporosis
- Interventions
- Parathyroid hormone (hPTH 1-34)
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Thyroid Disease, Parathyroid Diseases
- Interventions
- Non-narcotic group regimen, Narcotic group regimen
- Drug
- Lead sponsor
- MetroHealth Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Premature Infants
- Interventions
- cholecalciferal, cholecalciferol
- Dietary Supplement
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 23 Weeks to 32 Weeks
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis
- Interventions
- Paricalcitol, Cinacalcet
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 30
- States / cities
- Tempe, Arizona • Chula Vista, California • Los Angeles, California + 22 more
- Conditions
- Hypoparathyroidism, Hypocalcemia, Autoimmune Polyendocrine Syndrome Type 1, Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- Interventions
- Synthetic Human Parathyroid Hormone 1-34 pump
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 7 Years to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease
- Interventions
- Zemplar, 42 Ca carbonate absorption via single tracer method, Calcijex
- Drug · Procedure
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Disease, Secondary Hyperparathyroidism
- Interventions
- cinacalcet capsule, placebo, Standard of Care
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more
- Conditions
- Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
- Interventions
- TransCon PTH, Placebo
- Combination Product
- Lead sponsor
- Ascendis Pharma Bone Diseases A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 9
- States / cities
- San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 6 more
- Conditions
- 22q11.2 Deletion Syndrome
- Interventions
- NFC-1
- Drug
- Lead sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation, DiGeorge Syndrome, STAT 1 Gain of Function, STAT 3 Gain of Function, Hypomorphic RAG1 Deficiency, CD40 Ligand Deficiency, Mendelian Susceptibility to Mycobacterial Disease, GATA2 Associated Immunodeficiency, CD40 Deficiency, Hypomorphic RAG2 Deficiency, Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome, Omenn Syndrome, Chronic Granulomatous Disease
- Interventions
- Hematopoietic stem cell transplant (HSCT)
- Biological
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 5 Years to 40 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- DP001
- Drug
- Lead sponsor
- Deltanoid Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Tustin, California • Denver, Colorado + 3 more
- Conditions
- Multiple Endocrine Neoplasia, Pancreatic Neuroendocrine Tumors, Hyperparathyroidism
- Interventions
- Genome Sequencing, Data Review
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Osteoporosis
- Interventions
- Low protein diet
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 20 Years to 40 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Parathyroid Cancer, Primary Hyperparathyroidism, Pseudohypoparathyroidism, Inheritable Bone Diseases, Multiple Endocrine Neoplasia, Type 1
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 6 Months to 100 Years
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Overweight and Obesity, Vitamin D Deficiency, Magnesium Deficiency, Cardiovascular Risk Factor
- Interventions
- Vitamin D and magnesium, Vitamin D, Placebo
- Dietary Supplement
- Lead sponsor
- Drexel University
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- Teriparatide
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 40 Years to 59 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Secondary Hyperparathyroidism, End-Stage Renal Disease
- Interventions
- Paricalcitol, Calcitriol
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- Up to 16 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Gainesville, Florida • Orlando, Florida + 15 more
- Conditions
- Velocardiofacial Syndrome
- Interventions
- Challenging Our Minds Program
- Behavioral
- Lead sponsor
- State University of New York - Upstate Medical University
- Other
- Eligibility
- 12 Years to 16 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- Parathyroid Dysfunction, Adenoma
- Interventions
- Indocyanine green, SPY Portable Handheld Imaging
- Drug · Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Secondary Hyperparathyroidism, Hypercalcemia
- Interventions
- Cinacalcet HCl
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Primary Hyperparathyroidism
- Interventions
- Not listed
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 6
- States / cities
- Iowa City, Iowa • Lawrence, Kansas • Minneapolis, Minnesota + 3 more
- Conditions
- Parathyroid; Anomaly, Parathyroid Dysfunction, Hyperparathyroidism, Parathyroid Gland Adenoma
- Interventions
- Parakeet:The Parakeet Rapid Parathyroid Testing Kit is a rapid immunoassay designed to detect Parathormone (PTH) in a test sample.
- Device
- Lead sponsor
- Neurovision Medical Products Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Ventura, California
- Conditions
- Parathyroid Adenoma, Parathyroid Neoplasms, Parathyroid Hyperplasia, Parathyroid Cancer, Hypercalcemia, Primary Hyperparathyroidism
- Interventions
- NIRAF Detection Technology
- Device
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee